R Squared Ltd Makes New $205,000 Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

R Squared Ltd purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 2,450 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

A number of other large investors also recently modified their holdings of ITCI. AQR Capital Management LLC grew its holdings in Intra-Cellular Therapies by 33.5% in the 2nd quarter. AQR Capital Management LLC now owns 105,431 shares of the biopharmaceutical company’s stock worth $7,221,000 after buying an additional 26,486 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 214.5% in the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock worth $60,895,000 after buying an additional 606,358 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Intra-Cellular Therapies in the second quarter valued at $1,172,000. Creative Planning increased its holdings in shares of Intra-Cellular Therapies by 45.9% in the 2nd quarter. Creative Planning now owns 19,611 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 6,172 shares during the period. Finally, Ghisallo Capital Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 2nd quarter valued at $3,424,000. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $127.00 on Wednesday. Intra-Cellular Therapies, Inc. has a one year low of $62.78 and a one year high of $128.00. The company has a market capitalization of $13.46 billion, a price-to-earnings ratio of -145.98 and a beta of 0.70. The stock has a 50-day moving average of $94.97 and a 200 day moving average of $83.51.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million for the quarter, compared to the consensus estimate of $172.30 million. During the same period in the prior year, the business earned ($0.25) earnings per share. Intra-Cellular Therapies’s revenue was up 39.0% compared to the same quarter last year. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Thursday, January 23rd. They set a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating and issued a $100.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Morgan Stanley boosted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Baird R W downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Intra-Cellular Therapies currently has an average rating of “Moderate Buy” and an average price target of $102.15.

Insider Buying and Selling

In other news, CEO Sharon Mates sold 51,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.